Photo of Lucinda Osborne

Lucinda Osborne

Lucinda Osborne specialized in technology transactions in the life science sector with a particular emphasis on complex strategic collaborations as well as technology and product transfers and licensing arrangements in the context of mergers and acquisitions.

Chambers UK states that Lucinda “has devoted her career to life sciences collaboration and licence agreements” and notes that “[o]ne key client said: ‘She is great - she always delivers, the client care is fantastic, and she gives really pragmatic, speedy and good advice.’”

Lucinda regularly advised clients on cross border transactions. She had particular experience structuring and documenting global collaborations to reflect market practices and requirements in the U.S. Her expertise included the full range of commercial agreements that span the product life-cycle in the life sciences sector including clinical trial agreements, evaluation agreements, manufacturing and supply arrangements, distribution and other marketing agreements, and tenders.

The EU pharmaceutical industry landscape is in significant flux. There are many pressures to provide new therapies and to make them available more early and for as many qualifying patients as possible. In that context, the industry model and the role of exclusivity rights as a tool to stimulate innovation are being discussed. At the same time, discovering and developing new products is more complex and requires a collaborative effort. This happens against the background of new rules on medical devices and the protection of personal data, which are, for instance, relevant in assessing clinical effectiveness and relying on real world evidence.

Three members of the Covington European Life Sciences team will be speaking on these topics at the EU Pharmaceutical Law Forum being held in Brussels on 16-18th May.
Continue Reading Exploring the EU Horizon for Pharma